C. Baum and P. Kirschmeier, Preclinical and clinical evaluation of farnesyltransferase inhibitors, Current Oncology Reports, vol.20, issue.2, pp.99-107, 2003.
DOI : 10.1007/s11912-003-0096-5

D. End, G. Smets, A. Todd, T. Applegate, C. Fuery et al., Characterization of the antitumour effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro, Cancer Res, vol.61, pp.131-137, 2001.

J. De-bono, A. Tolcher, and E. Rowinsky, Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma, Seminars in Oncology, vol.30, issue.5, pp.79-92, 2003.
DOI : 10.1053/j.seminoncol.2003.08.010

R. Schiff, S. Massarweh, J. Shou, and C. Osborne, Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response, Clin Cancer Res, vol.9, pp.447-454, 2003.

D. Medina, P. Favre, G. Poirot, and M. , Multiple Targeting by the Antitumor Drug Tamoxifen: A Structure-Activity Study, Current Medicinal Chemistry-Anti-Cancer Agents, vol.4, issue.6, pp.491-508, 2004.
DOI : 10.2174/1568011043352696

URL : https://hal.archives-ouvertes.fr/inserm-00090772

R. Sutherland, L. Murphy, S. Foo, M. Green, M. Whybourne et al., High-affinity anti-oestrogen binding site distinct from the oestrogen receptor, Nature, vol.93, issue.5788, pp.273-275, 1980.
DOI : 10.1038/288273a0

J. Faye, S. Jozan, G. Redeuilh, E. Baulieu, and F. Bayard, Physicochemical and genetic evidence for specific antiestrogen binding sites., Proceedings of the National Academy of Sciences, vol.80, issue.11, pp.3158-3162, 1983.
DOI : 10.1073/pnas.80.11.3158

B. Kedjouar, D. Medina, P. Oulad-abdelghani, M. Payre, B. Silvente-poirot et al., Molecular Characterization of the Microsomal Tamoxifen Binding Site, Journal of Biological Chemistry, vol.279, issue.32, pp.34048-34061, 2004.
DOI : 10.1074/jbc.M405230200

URL : https://hal.archives-ouvertes.fr/inserm-00090773

R. Sutherland, R. Hall, and I. Taylor, Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells, Cancer Res, vol.43, pp.3998-4006, 1983.

F. Delarue, B. Kedjouar, F. Mesange, F. Bayard, J. Faye et al., Modifications of benzylphenoxy ethanamine antiestrogen molecules: influence affinity for antiestrogen binding site (AEBS) and cell cytotoxicity, Biochemical Pharmacology, vol.57, issue.6, pp.657-661, 1999.
DOI : 10.1016/S0006-2952(98)00347-5

URL : https://hal.archives-ouvertes.fr/inserm-00090781

S. Mandlekar, R. Yu, T. Tan, and A. Kong, Activation of caspase-3 and c-Jun NH2-terminal kinase-1 signaling pathways in tamoxifen-induced apoptosis of human breast cancer cells, Cancer Res, vol.60, pp.5995-6000, 2000.

S. Mandlekar, V. Hebbar, K. Christov, and A. Kong, Pharmacodynamics of tamoxifen and its 4-hydroxy and N-desmethyl metabolites: activation of caspases and induction of apoptosis in rat mammary tumours and in human breast cancer cell lines, Cancer Res, vol.60, pp.6601-6606, 2000.

F. Tamanoi, C. Gau, C. Jiang, H. Edamatsu, and J. Kato-stankiewicz, Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells, Cellular and Molecular Life Sciences, vol.58, issue.11, pp.1636-1649, 2001.
DOI : 10.1007/PL00000802

S. Doisneau-sixou, P. Cestac, J. Faye, G. Favre, and R. Sutherland, Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression, International Journal of Cancer, vol.10, issue.5, pp.789-798, 2003.
DOI : 10.1002/ijc.11263

S. Doisneau-sixou, P. Cestac, S. Chouini, J. Carroll, A. Hamilton et al., Contrasting Effects of Prenyltransferase Inhibitors on Estrogen-Dependent Cell Cycle Progression and Estrogen Receptor-Mediated Transcriptional Activity in MCF-7 Cells, Endocrinology, vol.144, issue.3, pp.989-998, 2003.
DOI : 10.1210/en.2002-220726

URL : https://hal.archives-ouvertes.fr/inserm-00090777

M. Poirot, D. Medina, P. Delarue, F. Perie, J. Klaebe et al., Synthesis, binding and structure???affinity studies of new ligands for the microsomal anti-estrogen binding site (AEBS), Bioorganic & Medicinal Chemistry, vol.8, issue.8
DOI : 10.1016/S0968-0896(00)00119-X

URL : https://hal.archives-ouvertes.fr/inserm-00090778

P. Skehan, R. Storeng, D. Scudiero, A. Monks, J. Mcmahon et al., New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening, JNCI Journal of the National Cancer Institute, vol.82, issue.13, pp.1107-1112, 1990.
DOI : 10.1093/jnci/82.13.1107

G. Steel and M. Peckham, Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity, International Journal of Radiation Oncology*Biology*Physics, vol.5, issue.1, pp.85-91, 1979.
DOI : 10.1016/0360-3016(79)90044-0

L. Brandes, A diphenylmethane derivative selective for the anti-estrogen binding site may help define its biological role, Biochemical and Biophysical Research Communications, vol.124, issue.1, pp.244-249, 1984.
DOI : 10.1016/0006-291X(84)90943-4

D. Medina, P. Payre, B. Bernad, J. Bosser, I. Pipy et al., Tamoxifen Is a Potent Inhibitor of Cholesterol Esterification and Prevents the Formation of Foam Cells, Journal of Pharmacology and Experimental Therapeutics, vol.308, issue.3, 2003.
DOI : 10.1124/jpet.103.060426

URL : https://hal.archives-ouvertes.fr/inserm-00090774

C. Ellis, M. Vos, M. Wickline, C. Riley, T. Vallecorsa et al., Tamoxifen and the Farnesyl Transferase Inhibitor FTI-277 Synergize to Inhibit Growth in Estrogen Receptor-Positive Breast Tumor Cell Lines, Breast Cancer Research and Treatment, vol.60, issue.1, pp.59-67, 2003.
DOI : 10.1023/A:1022105511409

G. Bompard, C. Puech, C. Prebois, F. Vignon, and G. Freiss, Proteintyrosine phosphatase PTPL1/FAP-1 triggers apoptosis in human breast cancer cells

H. Edamatsu, C. Gau, T. Nemoto, L. Guo, and F. Tamanoi, Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines, Oncogene, vol.19, issue.27, pp.3059-3068, 2000.
DOI : 10.1038/sj.onc.1203625

D. Croce, L. Vicent, G. Pecci, A. Bruscalupi, G. Trentalance et al., The Promoter of the Rat 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Gene Contains a Tissue-Specific Estrogen-Responsive Region, Molecular Endocrinology, vol.13, issue.8, pp.1225-1236, 1999.
DOI : 10.1210/mend.13.8.0333

B. Kedjouar, D. Medina, P. Faye, J. Poirot, and M. , Induction of apoptosis in human mammary carcinoma cells by (4-cumyl-phe- noxy)-ethyl-N-pyrrolidine-HCl, 92nd Annual Meeting of the Proceedings of the American Association for Cancer Research, pp.24-28, 2001.

P. Lebowitz, J. Eng-wong, B. Widemann, F. Balis, N. Jayaprakash et al., A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer, Clin Cancer Res, vol.11, pp.1247-1252, 2005.

J. Head and S. Johnston, New targets for therapy in breast cancer: Farnesyltransferase inhibitors, Breast Cancer Research, vol.23, issue.6, pp.262-268, 2004.
DOI : 10.1158/1078-0432.CCR-03-0412

L. Reyno, L. Seymour, D. Tu, S. Dent, K. Gelmon et al., -Diethyl-2-[4-(Phenylmethyl) Phenoxy]Ethanamine (BMS-217380-01) Combined With Doxorubicin Versus Doxorubicin Alone in Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19, Journal of Clinical Oncology, vol.22, issue.2, pp.269-276, 2004.
DOI : 10.1200/JCO.2003.04.075